2022
August
New neoantigen vaccine strategy aids checkpoint blockade in cold tumors
August 31, 2022
Given that checkpoint inhibition therapies have limited efficacy in tumors poorly infiltrated with T cells (immune cold tumors), combining these therapies with those attempting to increase antitumor T cell responses, such as vaccines, is warranted. Palmer et al. performed a phase 1/2 clinical trial assessing the safety and efficacy of an individualized neoantigen...
Inducing CAR-macrophages in the brain for local treatment
August 17, 2022
Despite aggressive treatment involving debulking surgery and chemoradiotherapy, glioblastoma multiforme (GBM) remains incurable. A major culprit for GBM recurrence and therapy resistance are self-renewing glioma stem cells (GSCs) that are left behind after surgery. Additionally, immunosuppressive macrophages are recruited to the tumor cavity in response to surgery-induced inflammation. Chen and Jing et al...
Targeting tumor defenses to enhance immunotherapy
August 10, 2022
In cancer immunotherapy, research is often focused on improving the immune attack against cancer. However, Kishton and Patel et al. recently turned their attention towards how cancer defends itself against immune attacks, and how these defense mechanisms could potentially be targeted to enhance immune-mediated killing of tumor cells. To investigate tumor defenses, the...
PD-1-high TILs: a predictive biomarker for ICB in lung cancer
August 3, 2022
Despite the promise of immune checkpoint blockade (ICB) therapy in treating non-small cell lung cancer (NSCLC), the majority of patients do not respond and toxicity remains a major issue. Identifying biomarkers of ICB efficacy could direct treatment to responsive patient populations, but remains an ongoing challenge in the cancer immunotherapy field. Now, reported...
